A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck.
Latest Information Update: 22 May 2020
At a glance
- Drugs Avasopasem manganese (Primary) ; Cisplatin (Primary)
- Indications Head and neck cancer; Mucositis; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Galera Therapeutics
- 18 May 2020 According to a Galera Therapeutics media release, the company will discuss summary of the preliminary findings from the study will be discussed in a virtual Key Opinion Leader (KOL) event on cisplatin-induced chronic kidney disease on Friday, May 22, 2020, from 10 a.m. to 11 a.m. EDT. An archived version of the webcast will be available in the News & Events section of the Investors page of Galera's website for 60 days following the event.
- 30 Apr 2020 According to a Galera Therapeutics media release, data from this trial were accepted for presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, taking place May 29-31, 2020.
- 27 Sep 2016 Results (n=46) published in the Galera Therapeutics Media Release